Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050647 · ClinicalTrials.gov registry record · Phase 1
Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01050647: Completed Phase 1 study, sponsored by Stanford University.
NCT01050647 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01050647, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Preterm birth is the leading cause of neonatal death and a significant cause of life long disability and health problems. It has been shown that the drug 17-hydroxyprogesterone caproate can help reduce the risk of preterm delivery in women with certain risk factors for preterm birth. We hope to learn whether this same medication can be used to prolong pregnancy in a group of patients in whom this medication has not been previously studied. Specifically, we hope to learn whether progesterone supplementation will delay delivery in women with pre-term, premature rupture of membranes (PPROM).
Interventions
- DRUG 17-Hydroxyprogesterone Caproate
- OTHER Caster Oil injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050647
The ClinicalTrials.gov registry entry for NCT01050647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 17-Hydroxyprogesterone Caproate is the first listed.
NCT01050647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01050647 about?
NCT01050647 is a clinical study titled "Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.". Preterm birth is the leading cause of neonatal death and a significant cause of life long disability and health problems. It has been shown that the drug 17-hydroxyprogesterone caproate can help reduce the risk of preterm delivery in women with certain risk factors for preterm birth. We hope to lear...
What is the current status of trial NCT01050647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01050647?
The interventions under investigation include: 17-Hydroxyprogesterone Caproate (DRUG), Caster Oil injections (OTHER).
Who is sponsoring clinical trial NCT01050647?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.